Closed unlabeled glass bottle beside a clean empty beaker on a stainless bench

Program Standards

Vegalab is a delivery technology and formulation partner, and our program standards are set out in advance so partners can see the fit before the first call. Every program we take on has a lawful pathway in its target market and a claim the evidence can support.

Programs we take on

We take on approved-molecule reformulation with a defined regulatory path, supplement and natural health product development against a monograph or a submission, cosmetic and professional formats, veterinary formats where the regulatory path is clear, and preclinical research support for qualified sponsors. Shared payloads with Beauty Science are in scope. These are the programs the platform was built for, and a one-page summary of payload, market and claim is the fastest way in.

Teal circle containing accepted work with declined categories shown as faint outlines outside it — Some categories of work are declined regardless of budget. Stating the limits before scoping saves time on both sides.

What every program has in common

Each program has a named regulatory pathway in its target market, a compound with documented provenance, and a claim supported by evidence for the finished product. Partners hold the regulatory standing and the clinical and administration guidance for their product; Vegalab delivers the formulation, stability data and GMP manufacture behind it. Programs built this way move faster, because nothing has to be reworked when the dossier is assembled.

Why the standard sits there

Our manufacturing and quality position rests on GMP standing and clear regulatory relationships across several jurisdictions, and every partner on the line benefits from that standing. Delivery technology also creates the most value where a compound's safety profile is already characterized: better delivery of a well-understood molecule is a product, while better delivery of an uncharacterized one is still a research question.

What we ask before a scope

Five questions. What is the compound and its documented provenance? What is the target market and product classification? What claim will the finished product make, and what evidence supports it? Who holds the regulatory standing, the sponsor or the brand? And what studies is the partner prepared to fund, since a feasibility result gains its value from the pharmacokinetic or stability program that follows it. Clear answers usually mean a fast start.

Key facts

Distributing an unapproved new drug intended for human use is prohibited in the US (21 U.S.C. 331, 355)
Human administration of an investigational compound requires an authorized trial application and ethics approval (21 CFR 312; EU Regulation 536/2014)
A supplement bearing a disease treatment or prevention claim becomes an unapproved drug (21 U.S.C. 321(g); 21 CFR 101.93)
GMP controls cover the whole facility, including equipment, cleaning and cross-contamination, so one product's practices can affect others made at the same site (ICH Q7; PIC/S GMP Guide)

How our delivery technology applies

Our platform is a manufacturing asset before it is a marketing story. Multi-layer encapsulation under GMP only holds value if the line stays auditable, which is why project selection is part of the technology offer rather than a legal afterthought. Partners get a delivery system with documented composition, batch records and stability data that a regulator can read.

If your project fits, send the five answers and we will scope it.